<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307719</url>
  </required_header>
  <id_info>
    <org_study_id>201944</org_study_id>
    <nct_id>NCT04307719</nct_id>
  </id_info>
  <brief_title>Prevalence of Carriers of Genetic Diseases in the Mexican Jewish Community</brief_title>
  <official_title>Carriers of Genetic Diseases in the Mexican Jewish Community</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anahuac University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anahuac University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Jewish Population is at an increased risk for genetic diseases, especially autosomal&#xD;
      recessive, thus, screening should be done to determine carrier status of several genetic&#xD;
      diseases. In the Mexican Jewish Community, which is a very diverse community (regarding&#xD;
      geographical origins), data of carrier status is unknown. The study aims to determine carrier&#xD;
      prevalence for over 300 diseases using commercially available panels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Preconceptional screening of genetic diseases is currently a underused and very&#xD;
      useful tool, especially in populations that are at risk to be carriers of genetic diseases,&#xD;
      such as the Jewish people, with carrier rates as high as 1:4 for any autosomal recessive&#xD;
      disease. The Mexican Jewish Community is one of these populations at-risk, and there is no&#xD;
      modern genetic research of the carrier rates in this community.&#xD;
&#xD;
      Goals: This research project in the Mexican Jewish Community aims to determine the prevalence&#xD;
      of carriers in the community in order to properly generate in the future, a systematic&#xD;
      carrier screening in the community.&#xD;
&#xD;
      Research Plan: The investigators propose a descriptive, observational, cross-sectional study,&#xD;
      in which a representative sample of the Mexican Jewish Community (Which composes of&#xD;
      Ashkenazi, Sephardic and Middle-Eastern Jews) of 250 patients, in which we´ll collect a&#xD;
      saliva sample with a collection kit. Furthermore, the sample will be sent to a private&#xD;
      commercial laboratory to perform the Comprehensive Carrier Screening to analyze the 301 genes&#xD;
      included in the test plus the 13 add-on genes.&#xD;
&#xD;
      Analysis: Other demographic variables will be collected from the patients at the time of the&#xD;
      sample collection to identify possible risk factors (geographical origin, number of Jewish&#xD;
      grandparents, history of genetic diseases, et. al) and a correlation analysis will be&#xD;
      performed to verify the strength of those risk factors on the carrier status of the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">April 19, 2021</completion_date>
  <primary_completion_date type="Actual">April 10, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Carrier Status for 300+ Genetic Diseases</measure>
    <time_frame>30 days after sample collection</time_frame>
    <description>Patients will be screened for over 300 genetic diseases to determine carrier status</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">208</enrollment>
  <condition>Genetic Predisposition</condition>
  <condition>Carrier, Gestational</condition>
  <arm_group>
    <arm_group_label>Mexican Jewish Community</arm_group_label>
    <description>Sample of Patients from the Mexican Jewish Community to be subjected to genetic testing</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva samples for commercially available DNA carrier screening panels&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Representative sample of the Mexican Jewish Community of child-bearing age, of both sexes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Jewish Origin in at least 1 grandparent&#xD;
&#xD;
          -  Members of one of the Jewish sub-Communities in Mexico City&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant Women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Morgenstern-Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anahuac University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Anáhuac México</name>
      <address>
        <city>Huixquilucan</city>
        <state>Estado De Mexico</state>
        <zip>52786</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Anahuac University</investigator_affiliation>
    <investigator_full_name>Dan Morgenstern-Kaplan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Carrier Screening</keyword>
  <keyword>Jewish</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

